Reporting to VP of Biology, the Associate Director/Director of Sample Strategy will lead external sample identification and access activities with academic, industrial, and non-profit organisations to enable timely acquisition of relevant human samples for both platform and biomarker activities.
You step into a role where a lot is already in motion.
The UK has a strong position in life sciences and health, with close collaboration between universities, research institutions and industry. This continues to drive demand for buildings that support complex and fast-growing organisations.
At the same time, new projects are underway and space within existing buildings is becoming available. The portfolio is expanding, and with that comes the need for someone who can actively drive leasing activity.
Constructive Bio is a VC-backed biotechnology startup based in Whittlesford, Cambridge. Our unique technology turns living cells into biofactories, creating sustainable new materials and therapeutics. With full control of the genetic sequence and code, we are exploring chemical space previously unreached by natural biology.
Do you want to help us improve human health and understand life on Earth? Make your mark by shaping the future to enable or deliver life-changing science to solve some of humanity’s greatest challenges.
About the role:
The Funding team at LifeArc has oversight of all grant funding activity across the organisation, including the continued development and maintenance of LifeArc’s funding policies and operating model as our funding offering continues to scale.
We have an exciting opportunity for a talented and highly motivated Laboratory Operations Manager to join Laverock Therapeutics, an early‑stage biotech company applying its proprietary gene‑silencing platform to the development of novel human therapeutics.
Talisman Therapeutics Ltd is a neuroscience drug discovery company based in Cambridge, UK. Talisman’s key expertise is in developing fully human cellular models that robustly capture the complex biology of neurological disease and implementing them for preclinical drug development, from target ID to IND-enabling studies. This is an exciting time to join the company as we continue to develop and expand our platform and portfolio of internal and external projects.
Proteotype Diagnostics is recruiting a Doctoral Candidate (DC14) as part of the HER-CARE Marie Skłodowska-Curie Doctoral Network, a European programme training the next generation of researchers in hereditary and early-stage breast cancer.
The project will focus on the development of circulating proteomic biomarkers for early breast cancer detection and prediction of treatment response, using Proteotype’s proprietary biomarker platform.
The doctoral candidate will:
Amsbio reports how researchers at the Graduate School of Medicine, Kyoto University (Japan) have cultured patient-derived colorectal cancer cells in 3D using their MatriMix 511 extracellular matrix (ECM).
In the race to bring new therapeutics to market, the biggest hurdles aren’t just scientific—they’re operational. Fragmented data and information fatigue can slow down even the most promising pipelines.
To help biotech leaders bridge these gaps, Digital Science has launched a comprehensive resource hub focused on Advancing R&D Excellence. This suite of resources provides the framework needed to make confident, evidence-based decisions at every stage of discovery.